4th Annual Targeted Radiopharmaceuticals Summit - Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy
SNMMI 2025: First-in-class antibody radioconjugate ATNM-400 exhibits potent anti-tumor activity and overcomes resistance to enzalutamide and 177Lu-PSMA-617 in prostate cancer models
ATNM-400 AACR 2025: More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models
Actimab-A AACR 2025: Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia
Actinium Pharmaceuticals KOL Presentation: Discussing Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-BKOL Event with Dr. Sergio Giralt
